Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Lela M. Lucy"'
Autor:
Teresa Bernal del Castillo, Jun Ho Jang, Richard Noppeney, S. Songer, Anna Candoni, Hartmut Döhner, Irwindeep Sandhu, Mark D. Minden, Agnieszka Wierzbowska, John F. Seymour, Haifa Kathrin Al-Ali, Christian Recher, C.L. Beach, Heidi McIntyre, Lela M. Lucy, Richard Stone, Aleksandra Butrym, Dominik Selleslag, James Cavenagh, Andre C. Schuh, Hervé Dombret, Jose F Falantes, Giovanni Martinelli, Rajat Kumar
Publikováno v:
Blood. 126:291-299
This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts. Bef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd98a39bf1e28697c44ff96640513c4
https://doi.org/10.1182/blood-2015-01-621664
https://doi.org/10.1182/blood-2015-01-621664
Autor:
Joan Bladé, Wiesław Wiktor Jędrzejczak, Zhinuan Yu, Mohamad A. Hussein, Jerome B. Zeldis, S. Vincent Rajkumar, Lela M. Lucy, Marta Olesnyckyj, Laura Rosiñol, John G. Catalano, Rob Knight
Publikováno v:
Journal of Clinical Oncology. 26:2171-2177
Purpose The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown. The goal of this study was to compare thalidomide plus dexamethasone versus placebo plus dexamethasone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e07e096872264ca4be03e3667d2a4f
https://doi.org/10.1200/jco.2007.14.1853
https://doi.org/10.1200/jco.2007.14.1853
Autor:
Aleksandra Butrym, Hervé Dombret, R. Nopenney, John F. Seymour, Christian Recher, Giovanni Martinelli, Andre C. Schuh, James D. Cavenagh, Haifa Kathrin Al-Ali, S. Songer, Anna Candoni, Dominik Selleslag, Irwindeep Sandhu, C.L. Beach, Jose F Falantes, Agnieszka Wierzbowska, Hartmut Döhner, Rajat Kumar, Richard Stone, Mark D. Minden, Heidi McIntyre, Jun Ho Jang, Lela M. Lucy, T. Bernal del Castillo
Publikováno v:
Leukemia Research. 39:S63-S64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69ee3b8e4b57d8a3129703ad33cb3a01
https://doi.org/10.1016/s0145-2126(15)30125-9
https://doi.org/10.1016/s0145-2126(15)30125-9
Autor:
Jose F Falantes, John F. Seymour, Mark D. Minden, Aleksandra Butrym, R. Nopenney, Heidi McIntyre, T. Bernal del Castillo, Giovanni Martinelli, Irwindeep Sandhu, Jun Ho Jang, Agnieszka Wierzbowska, Richard Stone, Rajat Kumar, Haifa Kathrin Al-Ali, Lela M. Lucy, James D. Cavenagh, S. Songer, Dominik Selleslag, Anna Candoni, Andre C. Schuh, Hervé Dombret, C.L. Beach, Hartmut Döhner, Christian Recher
Publikováno v:
Leukemia Research. 39:S48-S49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3747476b4cf9af0eef8714cc56b49078
https://doi.org/10.1016/s0145-2126(15)30097-7
https://doi.org/10.1016/s0145-2126(15)30097-7
Autor:
Thomas Moehler, Roman Hájek, Axel Glasmacher, Jens Hillengass, Elisabeth Kueenburg, Thierry Facon, Tadeusz Robak, Peter Liebisch, Cyrille Hulin, Joan Bladé, Claire Pattou, Martin Kropff, Stefan Goranov, Hervé Avet-Loiseau, Lela M. Lucy, Honorata Giongco Baylon, Robert Zerbib, Tommaso Caravita
Background Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma. Design and Methods We conducted an international, ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7f251d396957fda393397208b2115c7
https://europepmc.org/articles/PMC3342984/
https://europepmc.org/articles/PMC3342984/
Autor:
Mark D. Minden, Donna Dougherty, Hartmut Döhner, Lewis R. Silverman, Dominique Gambini, Hervé Dombret, C.L. Beach, Valeria Santini, Randy Hinkle, Pierre Fenaux, John F. Seymour, Ghulam J. Mufti, Lela M. Lucy, Stephen Songer, Richard Stone
Publikováno v:
Blood. 126:3754-3754
Background: AML and MDS are distinct, though largely overlapping, diseases, especially in older patients (pts) (Vardiman, Blood, 2008). Injectable AZA is the reference first-line treatment (Tx) for pts with higher-risk (HR) MDS ineligible for alloSCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8965a8948f0dbd7e346292f15c7b89d7
https://doi.org/10.1182/blood.v126.23.3754.3754
https://doi.org/10.1182/blood.v126.23.3754.3754
Autor:
Rajat Kumar, Haifa Kathrin Al-Ali, Giovanni Martinelli, John F. Seymour, C.L. Beach, Agnieszka Wierzbowska, Teresa Bernal del Castillo, Jun Ho Jang, Mark D. Minden, Aleksandra Butrym, Hervé Dombret, Christian Recher, Irwindeep Sandhu, Heidi McIntyre, James D. Cavenagh, Dominik Selleslag, Andre C. Schuh, Hartmut Döhner, Lela M. Lucy, Anna Candoni, Jose F Falantes, Stephen Songer, Richard Stone
Publikováno v:
Blood. 124:621-621
Background: Overall survival (OS) in older patients (pts) with AML and poor-risk cytogenetics is only ~2-3 months (mos) (Burnett, Cancer, 2007). Often these pts receive only palliative treatment (Tx) with best supportive care (BSC). Low-dose Ara-C (L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf404d2a6b8ed70fedbad9b1f9361aa5
https://doi.org/10.1182/blood.v124.21.621.621
https://doi.org/10.1182/blood.v124.21.621.621
Autor:
James D. Cavenagh, John F. Seymour, Irwindeep Sandhu, Anna Candoni, Teresa Bernal del Castillo, Hartmut Döhner, Jun Ho Jang, Richard Stone, Agnieszka Wierzbowska, Dominik Selleslag, Heidi McIntyre, C.L. Beach, Aleksandra Butrym, Jose F Falantes, Rajat Kumar, Andre C. Schuh, Giovanni Martinelli, Lela M. Lucy, Haifa Kathrin Al-Ali, Stephen Songer, Hervé Dombret, Christian Recher, Mark D. Minden
Publikováno v:
Blood. 124:10-10
Background: AML is characterized by molecular heterogeneity; morphology and genetic alterations are important prognostic factors (Weinberg, 2009). In the large, phase 3, multicenter, randomized AZA-AML-001 study, AZA treatment (Tx) prolonged median o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e043b8be98b5320cfd5a58cdea88624
https://doi.org/10.1182/blood.v124.21.10.10
https://doi.org/10.1182/blood.v124.21.10.10
Autor:
Xiaolong Luo, Kyle J. MacBeth, Ludmila Danilova, Tao Shi, James G. Herman, Leslie Cope, C.L. Beach, Lela M. Lucy
Publikováno v:
Blood. 118:3815-3815
Abstract 3815 Background: Azacitidine (AZA) is approved for the treatment of patients with higher-risk myelodysplastic syndromes (MDS) and increases median overall survival (OS) by 9.5 months compared with conventional care regimens (CCR). However, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5efa81331c55549254b1bf55f7e66da
https://doi.org/10.1182/blood.v118.21.3815.3815
https://doi.org/10.1182/blood.v118.21.3815.3815
Autor:
Jay Backstrom, John F. Seymour, C.L. Beach, Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, Carlo Finelli, Guillermo Sanz, Lela M. Lucy
Publikováno v:
Blood. 116:1856-1856
Abstract 1856 Background: Sixty to 80% of patients (pts) with higher-risk myelodysplastic syndromes (MDS) require RBC transfusions to manage symptoms of anemia. Transfusion-associated complications include iron overload, transmitted infections, alloi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc0432bf7a3de8513b9085383dbe2930
https://doi.org/10.1182/blood.v116.21.1856.1856
https://doi.org/10.1182/blood.v116.21.1856.1856